|
Guest
|
Most recent articles on prostate cancer and metastasis:
Our experience on pain palliation of bone metastasis with Sr-89 or
Sm-153 in cancer patients resistant to a conventional analgesic
therapy. A retrospective study.
Montesano T, Giacomobono S, Acqualagna G, Colandrea M, Di Nicola A,
Travascio L, Giancamerla M, D'Apollo R, Toteda M, Ugolini F, Filesi M,
Ronga G.
Clin Ter. 2009 May-Jun;160(3):193-9.
Cystoprostatectomy as a treatment of prostate cancer involving the
bladder neck.
Kumazawa T, Tsuchiya N, Saito M, Inoue T, Narita S, Horikawa Y, Yuasa
T, Satoh S, Kato T, Nanjyo H, Habuchi T.
Urol Int. 2009;83(2):141-5.
An elusive tumor in a man who has evidence of prostate cancer
metastasis.
Boyer BP, Boyer MJ.
JAAPA. 2009 Aug;22( :22, 24-5.
The application of nanotechnology for the treatment of metastatic
prostate cancer.
Fitzpatrick JM.
BJU Int. 2009 Sep;104(6):i.
Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor
angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho
GTPase activation.
Cho SG, Yi Z, Pang X, Yi T, Wang Y, Luo J, Wu Z, Li D, Liu M.
Cancer Res. 2009 Sep 1;69(17):7062-70.
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scimedweb at (no spam) mail.com) |
|
|
